The Cancer Institute of New Jersey (CINJ) prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated States in our Nation. As a matrix and consortium cancer center that has been continuously funded by the NCI CCSG mechanism since 1997, CINJ conducts state of the art research, patient care, and outreach/education. CINJ is currently comprised of 161 members from a total of 32 academic departments who hold over $92.9 million total peer-reviewed support, $61.1 million annual direct support, $28.9 million total NCI support and $18.7 million annual direct NCI support (a 20% Increase in NCI support since the time ofthe last submission in 2004). Since the appointment of Dr. Robert S. DiPaola as center director in September, 2008, accrual onto investigator initiated therapeutic clinical trials has more than doubled;17 new faculty were recruited in multiple areas including Basic Science, Clinical Science, Public Health Science, and Systems Biology/Bioinformatics;the Consortium relationship with Princeton University and Rutgers University was strengthened and formalized;the State's cancer registry and SEER contract was moved to CINJ;and an additional four recruitment searches were launched. CINJ now has six established Research Programs: Cell Death and Survival Signaling;Genomic Instability and Tumor Growth;Cancer Pharmacology and Preclinical Therapeutics;Clinical Investigations;Carcinogenesis and Chemoprevention;and Cancer Prevention and Control. CINJ supports 14 Shared Resources, including: Flow Cytometry and Cell Sorting;Functional Genomics;Transgenic and Knockout Mouse;Pharmacokinetics and Pharmacodynamics;Histopathology and Imaging;Biorepository Service;Bioinformatics;Biometrics;Research Pharmacy;Office of Human Research Services;Centralized Education and Training for Clinical Research Personnel; Small Animal Imaging (developing);Metabolomics (developing) and Epidemiology Services (developing). Overall, CINJ has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has State-wide authority beyond the University matrix, thus establishing an environment to foster and formalize a Vision of Transdisciplinary and Translational Research within and beyond the University matrix. We are requesting CCSG support for Senior leadership, Program Leadership, Planning and Evaluation, Developmental Funds, Administration, Shared Resources, Protocol Review and Monitoring, Protocol Specific Research Support, and Data and Safety Monitoring.

Public Health Relevance

The mission ofthe CINJ is to conduct innovative basic, clinical and population research that: 1. Expands our understanding of the etiology and biology of cancer. 2. Facilitates the rapid translation of laboratory-based discoveries into human studies. 3. Develops new approaches and interventions for cancer prevention that decrease cancer incidence and mortality. 4. Develops new and better therapies to decrease suffering and mortality from cancer.(2) Fulfillment of this mission will be achieved in an environment that values diversity and fairness(3), and one that is dedicated to the development of the next generation of physicians and scientists and to delivering comprehensive and compassionate patient care.(4)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-16S3
Application #
8725778
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-03-01
Project End
2017-02-28
Budget Start
2013-07-01
Budget End
2014-02-28
Support Year
16
Fiscal Year
2013
Total Cost
$49,999
Indirect Cost
$18,553
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08903
DiPaola, Robert S; Chen, Yu-Hui; Bubley, Glenn J et al. (2015) A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 68:365-71
Mukherjea, Arnab; Wackowski, Olivia A; Lee, Youn Ok et al. (2014) Asian American, Native Hawaiian and Pacific Islander tobacco use patterns. Am J Health Behav 38:362-9
Wan, Liling; Lu, Xin; Yuan, Salina et al. (2014) MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer Cell 26:92-105
Steinberg, Michael B; Zimmermann, Mia Hanos; Delnevo, Cristine D et al. (2014) E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices. J Gen Intern Med 29:1444-50
Simhadri, Srilatha; Peterson, Shaun; Patel, Dharm S et al. (2014) Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. J Biol Chem 289:24617-29
Chandran, Urmila; McCann, Susan E; Zirpoli, Gary et al. (2014) Intake of energy-dense foods, fast foods, sugary drinks, and breast cancer risk in African American and European American women. Nutr Cancer 66:1187-99
Zimmermann, M H; Richardson, D L; Manderski, M T B et al. (2014) Relighting behaviour among cigarette smokers seeking treatment: implications for tobacco treatment and policy. Int J Clin Pract 68:1358-63
Zheng, Hanqiu; Shen, Minhong; Zha, Yin-Lian et al. (2014) PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell 26:358-73
Gong, Zhihong; Ambrosone, Christine B; McCann, Susan E et al. (2014) Associations of dietary folate, Vitamins B6 and B12 and methionine intake with risk of breast cancer among African American and European American women. Int J Cancer 134:1422-35
Faiena, Izak; Singer, Eric A; Pumill, Chris et al. (2014) Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review). Int J Oncol 45:2193-8

Showing the most recent 10 out of 191 publications